Survival in heart failure
- Heart failure (HF) is an enormous public health burden with 300,000 new deaths each year and a prevalence of 6.5 million people in the United States1.
- There is large variability in HF prognosis2, and there is a need for a broader systemic approach to identify novel circulating markers of HF progression.
- One of the most robust and validated models for mortality prediction in HF patients is the Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) Score3.
- Additionally, the use of N-Terminal pro-B-Type Natriuretic Peptide (NTproBNP) has been shown to be valuable in prognosis prediction4.
- It is uncertain if the plasma proteome is a better prediction tool for the course of HF compared to the clinical risk score MAGGIC and NTproBNP.
PosterDementia risk from middle age
In the US the number of individuals affected by dementia is expected to double by 2040. Thus, tools enabling identification of at-risk individuals earlier in disease progression, or before disease onset, are vital.
PosterLung Cancer risk in ever smokers
Development and validation of a blood-based protein-only predictor of 5-year lung cancer risk in ever smokers.
Urinary proteome and its application to predict cardiovascular risk in patients with stable Coronary Heart Disease.